Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
264 hedge funds and large institutions have $4.54B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2019 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 81 increasing their positions, 112 reducing their positions, and 47 closing their positions.
107% more call options, than puts
Call options by funds: $17.2M | Put options by funds: $8.32M
100% more funds holding in top 10
Funds holding in top 10: 6 → 12 (+6)
16% more capital invested
Capital invested by funds: $3.91B → $4.54B (+$634M)
3% less funds holding
Funds holding: 272 → 264 (-8)
15% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 47
28% less repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 112
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$65.8M |
| 2 |
PC
Paulson & Co
New York
|
+$38.8M |
| 3 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$38.6M |
| 4 |
William Blair Investment Management
Chicago,
Illinois
|
+$35.7M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$33.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$34.1M |
| 2 |
BlackRock
New York
|
-$22.1M |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$19.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$17.6M |
| 5 |
Goldman Sachs
New York
|
-$17.4M |
HZNP Hedge Fund Activity: Q3 2019 in Review
264 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q3 2019, worth a combined $4.54B — up 16% from $3.91B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of HZNP and 40 opened new positions — a net loss of 7 holders — while 112 trimmed existing stakes and 81 added.
The largest buyer was Invesco, adding an estimated $65.8M. The largest seller was Northern Trust, cutting an estimated $34.1M.
- 264 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q3 2019, down from 272 in Q2 2019.
- Funds reported $4.54B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q3 2019, up 16% quarter-over-quarter.
- 40 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q3 2019 and 47 closed out, a net change of -7 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q3 2019 was Invesco, an estimated $65.8M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q3 2019 was Northern Trust, an estimated $34.1M sold.
Based on aggregated 13F filings for Q3 2019.